Gene Therapy · us
Bringing Split Retinal Layers Back Together: Early ATSN-201 Trial Shows Vision Improvements
For X-linked retinoschisis, ATSN-201 brought at least one measure of visual function to the improvement threshold in seven of nine patients who received the key dose. Imaging and functional changes offer hope, but whether efficacy can be established remains a question for the Phase 3 trial now enrolling patients.
For patients with X-linked retinoschisis, the cause of blurred vision lies within the retinal tissue and often cannot be corrected with glasses. On October 7, Atsena Therapeutics announced preliminary results for its gene therapy ATSN-201: some patients showed both closure of retinal splits and improvements in visual function. This moves expectations for treatment a step beyond repair seen on imaging toward how much patients can actually see.
This inherited disease is associated with mutations in the RS1 gene, primarily affects males, and is usually diagnosed in childhood. Abnormal splitting of the retinal layers can cause progressively worsening vision loss. ATSN-201 is administered by subretinal injection and uses the AAV.SPR viral vector, which can spread beyond the injection area. It is designed to reach photoreceptors in the central retina while reducing the need to surgically detach the fovea directly.
The data come from the Phase 1/2 portion of the LIGHTHOUSE trial, which enrolled 21 participants. Of these, 18 received treatment in one eye, including three children, while three untreated adults served as controls. The adult data released by the company cover 12 months of follow-up, while the pediatric data cover six months. The University of Florida's UF Innovate also relayed the announcement, noting that the findings were scheduled for presentation at the American Academy of Ophthalmology annual meeting, held October 9–12 in New Orleans.
Among nine patients who received the dose selected for Phase 3, seven met the response criteria for at least one measure of visual function: six met the improvement threshold on microperimetry, three met the criteria for visual acuity improvement, and five showed a structural response on optical coherence tomography (OCT). Microperimetry assesses light sensitivity at different locations in the retina. The trial defined a response as an average improvement of at least seven decibels across eligible central test points, while a visual acuity response required a gain of at least ten letters in best-corrected or low-luminance testing. None of these patients' untreated fellow eyes met the response criteria described above.
Longer follow-up also offers clues about whether efficacy persists. At 36 months of follow-up, one of the earliest treated patients continued to show closure of the foveal split, with sustained improvements in microperimetry and visual acuity. However, this remains the long-term experience of a single patient and does not mean that everyone can maintain the same effects. The company said that no drug-related serious adverse events have been reported to date and no dose-limiting toxicities have occurred. The small sample remains insufficient to rule out rarer risks.
Interpreting these results also requires attention to the source and scope of the evidence. Atsena's website and GlobeNewswire carry the same company announcement, and UF Innovate's brief report links directly back to that announcement without providing independent clinical validation. The pooled dose analysis of nine patients spans different cohorts and follow-up periods, and the announcement does not yet provide complete statistical data sufficient to assess the certainty of efficacy. The corresponding improvements in retinal structure and visual function are a valuable signal, but they are not yet sufficient to establish a treatment benefit.
The next key step is the randomized controlled Phase 3 LIGHTHOUSE trial, which is expected to enroll 76 patients aged five years and older, with microperimetry response at 52 weeks as the primary assessment. According to the company's timeline, enrollment is expected to be completed in the first quarter of 2027, with primary results announced in the first half of 2028 and a biologics license application targeted for the second half of that year. These remain development plans. ATSN-201 has not yet been approved, and whether the early signs of repair can translate into reliable, lasting improvements in vision still requires confirmation in a larger trial.